Pasireotide solution. 帕瑞肽.注射液

Pasireotide is a synthetic somatostatin analogue, mainly used to treat Cushing’s disease and acromegaly. It inhibits abnormal hormone secretion by binding to somatostatin receptors (SSTR), thereby relieving related symptoms. As a prescription drug, it must be used strictly in accordance with the doctor’s instructions.

Core effects and indications
Treatment of Cushing’s disease: by inhibiting the secretion of excessive adrenocorticotropic hormone (ACTH) by pituitary tumors, reducing cortisol levels, and improving symptoms such as central obesity and hypertension. 1.
Control of acromegaly: reducing the secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1), relieving symptoms such as hand and foot hypertrophy and joint pain. 2.
Pharmacological mechanism
Receptor targeting: mainly acts on somatostatin receptor subtypes (SSTR5 and SSTR2) to inhibit hormone release.
Long-term sustained release: requires subcutaneous injection, slow release of the drug, and long-term efficacy.
Usage and side effects
Usage: usually injected once every 28 days, and the dose needs to be adjusted according to the condition. 1.
Common side effects: 2.
Gastrointestinal reactions (such as nausea and diarrhea);
Increased blood sugar (blood sugar needs to be monitored, use with caution in patients with diabetes);
Pain or nodules at the injection site.
Serious risks: rare bradycardia, gallstones, elevated liver enzymes, etc., need to seek medical attention in time. 3.
Precautions and contraindications
Contraindications: Patients who are allergic to drug ingredients and patients with severe liver and kidney dysfunction are prohibited.
Drug interactions: May affect the efficacy of hypoglycemic drugs, cyclosporine, etc., and the doctor needs to be informed of the drugs being used.
Special populations: Pregnant and lactating women and children need to evaluate the benefits and risks before use.
Medical guidance
Pasireotide needs to be used under the guidance of a professional doctor, and hormone levels, blood sugar and imaging evaluations need to be regularly reviewed during treatment. If serious adverse reactions occur or the condition worsens, the drug should be stopped immediately and the doctor should be consulted.